
Zura Bio Limited Class A Ordinary Shares Share Price
ZURAZura Bio Limited Class A Ordinary Shares Stock Performance
Open $1.93 | Prev. Close $1.93 | Circuit Range N/A |
Day Range $1.93 - $2.00 | Year Range $0.97 - $5.07 | Volume 9,069 |
Average Traded $1.97 |
Zura Bio Limited Class A Ordinary Shares Share Price Chart
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Zura Bio Limited Class A Ordinary Shares Historical Data
Day | Open | Close | Change % |
---|---|---|---|
16-Sep-25 | $1.93 | $1.98 | +0.00% |
16-Sep-25 | $1.93 | $1.98 | +2.86% |
15-Sep-25 | $1.98 | $1.92 | -3.52% |
12-Sep-25 | $2.04 | $1.99 | -1.92% |
11-Sep-25 | $2.10 | $2.03 | -2.45% |
10-Sep-25 | $2.12 | $2.08 | -5.45% |
09-Sep-25 | $2.23 | $2.20 | -0.90% |